Objectives: The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture.
Methods: Forty-six women (mean age 75 years) who underwent surgical treatment for intertrochanteric or femoral neck fractures due to minor trauma were divided into two groups according to the order of presentation. One group (26 patients; mean age 77+/-5 years) received oral risedronate 5 mg/day after the fifth postoperative day, while the other group (20 patients; mean age 73+/-6 years) received no drug treatment. Patients who had been on treatment for Paget's disease or osteoporosis or those with renal failure were excluded. Urine samples were collected from all the patients on the second day of hospitalization and at the end of three months to measure N-telopeptide levels, one of the bone turnover markers, with the use of the Osteomark NTx ELISA laboratory kit.
Results: The mean urine N-telopeptide level decreased by 49.7% at the end of three months of treatment with risedronate (p<0.0001), whereas there was a 5.8% increase in the N-telopeptide level of the control group. The two groups differed significantly with respect to the levels of bone resorption at the end of three months (p<0.0001).
Conclusion: Risedronate treatment was found effective in decreasing bone resorption and thus in reducing the risk for refractures in patients with hip fractures due to minor trauma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation and analysis of efficacy in bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Hua Xi Kou Qiang Yi Xue Za Zhi
February 2025
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Dept. of Pharmacy, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Objectives: This study aimed to analyze the influence of drug factors on the efficacy of bisphosphonate for chronic nonbacterial osteomyelitis to provide a reference for clinical treatment and promote clinical rational drug use by evaluation of effectiveness and safety of bisphosphonate treatment of chronic nonbacterial osteomyelitis.
Methods: Literature on the treatment of chronic nonbacterial osteomyelitis by using bisphosphonate was collected and analyzed from PubMed, Medline, Embase, Cochrane, ISI Web of Knowledge, CNKI, VIP, and Wanfang databases.
Results: A total of 489 cases were collected, with an average complete response rate of clinical presentation, laboratory tests and imaging findings of 80.
Engineering dimer mutants of human geranylgeranyl pyrophosphate synthase.
PLoS One
January 2025
Department of Biochemistry, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
Geranylgeranyl pyrophosphate synthase (GGPPS), a key enzyme in protein prenylation, plays a critical role in cellular signal transduction and is a promising target for cancer therapy. However, the enzyme's native hexameric quaternary structure presents challenges for crystallographic studies. The primary objective of this study was to engineer dimeric forms of human GGPPS to facilitate high-resolution crystallographic analysis of its ligand binding interactions.
View Article and Find Full Text PDFEldecalcitol Add-On to Risedronate Reduces Bone Loss from Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
J Clin Endocrinol Metab
January 2025
Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Context: Aromatase inhibitors (AIs) cause bone loss and increase fracture risk in women with hormone receptor-positive early-stage breast cancer (HR+EBC). Bone antiresorptive agents are recommended for patients at risk of fragility fractures. Eldecalcitol, combined with bisphosphonate, increases bone mineral density (BMD) in primary osteoporosis.
View Article and Find Full Text PDFBisphosphonate drug holidays in osteoporosis according to fracture risk profile.
Osteoporos Int
December 2024
Department of Rheumatology, Hospital Clínic, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Unlabelled: We analyzed the incidence of fractures and changes in bone mineral density and bone turnover markers in 264 patients who discontinued bisphosphonates. Fractures were recorded in 12.3%.
View Article and Find Full Text PDFTibial Insufficiency Fracture with Characteristics of an Atypical Fracture: A Rare Case and Literature Review.
Medicina (Kaunas)
November 2024
Department of Orthopedic Surgery, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-Ro, Yeongdeungpo-Gu, Seoul 07345, Republic of Korea.
Article Synopsis
- - Osteoporosis is increasingly common due to an aging population, leading to more patients using bisphosphonates for treatment, which can prevent fractures but also cause atypical insufficiency fractures over time.
- - A case study of a 76-year-old woman on long-term bisphosphonate therapy revealed an atypical insufficiency fracture in her tibia, which was confirmed through imaging and examination.
- - After conservative treatment failed, the patient underwent surgery and successfully healed, highlighting the need for clinicians to investigate unexplained pain in weight-bearing bones among individuals on prolonged bisphosphonate therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!